We are pleased to announce that Prof. Dr. Wei Wu has been appointed Section Editor-in-Chief of the “Nanomedicine and Nanotechnology” Section in Pharmaceutics (ISSN: 1999-4923). With his extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.

Prof. Dr. Wu is a professor at the Fudan University School of Pharmacy, Shanghai, China, and the director of the Fudan-Ruixing Joint Laboratories of Pharmaceutical Nanotechnology. He was the Vice Dean of his school and Deputy Director of the Institute of Pharmacy. He is currently the Vice President of Pharmaceutics and Particle Design Chapter of the China Particuology Society and the Vice President of Pharmaceutical Dosage Forms of the Traditional Chinese Medicine Committee of the World Union of TCM. His expertise is in nanomedicine, biopharmaceutics, and pharmaceutical nanotechnology. He has published more than 300 peer-reviewed publications in prestigious journals on pharmaceutics, drug delivery, and nanomedicines. A full list of his publications can be found here.

Prof. Dr. Wu and coworkers developed new types of NIR-I and NIR-II fluorophores with absolute aggregation-caused quenching (ACQ) properties for accurate bioimaging and quantification of drug nanocarriers. His group established the basic concepts and methodologies regarding nanocarrier analysis and particokinetics. He has also been among the World's Top 2% Scientists (annual and career) for several consecutive years in pharmacology and toxicology, according to the list created by researchers from Stanford University. He has also been awarded for his research and academic excellence, including New Century Excellent Talent of Ministry of Education, Shanghai Excellent Discipline Leaders, Shanghai Twilight Scholars, and Distinguished Lectureship by the Nagai Foundation Tokyo.

The following is a short Q&A with Prof. Dr. Wei Wu, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:

1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
Pharmaceutics has established a platform for communication and dissemination of knowledge within and outside of the pharmaceutics and drug delivery community. In the past, I benefited significantly from Pharmaceutics as an author, and I am satisfied for contributing to the scientific community in the role of a reviewer or an Editorial Board Member. To be a Section Editor-in-Chief, I regard it as a great opportunity to better serve the pharmaceutics and drug delivery community.

2. What are your plans and vision for the Section and the journal?
As Pharmaceutics has established its place and influence in the cross-field of pharmaceutics, drug delivery, and nanomedicines, my vision for it is steady growth, serving the scientific community with more high-quality contributions, more open access publications, and continuously increasing impact. In view of the booming research trends in nanomedicine and nanotechnology, my vision is to continuously lead the Sections and make growing contributions to the development of Pharmaceutics.

3. What does the future of this field of research look like?
Against the backdrop of the rapid development of innovative drugs and delivery systems, the field of pharmaceutics has experienced continuous growth in recent decades, and this trend will surely continue because of the demands of precision medicine for delicately orchestrated delivery strategies and delivery systems. That said, all endeavors in the discovery stages will only lead to the prosperity of pharmaceutics. Nonetheless, in the future, pharmaceutics may welcome new active ingredients spanning from small molecules to biomacromolecules and to new combinations and compounds with multiple components, which may challenge and push forward the development of theories, mindsets, and technologies in pharmaceutics and drug delivery.

4. What do you think of the development of open access in the publishing field?
Open access publication definitely benefits the scientific community by offering free access. However, excessive commercialization by compromising article quality would stymie the development of open access scientific publishing. By adhering to strict peer review standards, open access publishing may flourish, switching to a virtuous circle.

We warmly welcome Prof. Dr. Wei Wu as the new Section Editor-in-Chief and we look forward to him leading Pharmaceutics to many more milestones.